Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)
Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Aleix Prat(University of Padua), Antonia Perelló, Juan Miguel Cejalvo(Universitat de València), David Sternberg(Daiichi Sankyo (United States)), Maria-Eva Pérez-Lopez, Xavier González(Breast Cancer Research Foundation), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Juan Antonio Guerra(Hospital Universitario de Fuenlabrada), J.M. Ferrero-Cafiero(Solti), Juan de la Haba-Rodríguez(Instituto Maimónides de Investigación Biomédica de Córdoba), Pilar Sánchez Henaréjos, M. Borrell Puy(Vall d'Hebron Hospital Universitari), Tomás Pascual(Breast Cancer Research Foundation), K. Amillano Parraga(Hospital Universitari Sant Joan de Reus), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Alba González-Haba, Encarnación González‐Flores(Hospital Universitario Virgen de las Nieves), Javier Salvador Bofill, Fumitaka Suto(Daiichi Sankyo (United States)), Dalila Sellami(Daiichi Sankyo (United States)), Santiago González-Santiago(Università Cattolica del Sacro Cuore), Elena Gálve(Hospital de Basurto), Serafín Morales(Hospital Universitari Arnau de Vilanova), Yenlik Zheteyava(Daiichi Sankyo (United States)), Samyukta Chillara, Josefina Cruz(Hospital Universitario de Canarias), Sergio Hoyos(Hospital Universitario Rey Juan Carlos), Mariana Paes Dias(The Netherlands Cancer Institute), Montse Muñoz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Clara Martínez-Vila(Althaia)
Cited by 3
Related Papers
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
|Cancer Research|2017|480
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340